Enterosgel Clinically Proven
Enterosgel well known anti-toxins gastro-absorbent.
To see publications please follow the link PUBMED Enterosgel
The Medsilica Group is the first company in the Pacific Region to employ Artificial Intelligent Robots.
According to Dr.Vladimir Milushkin, Medsilica Group’s CEO, – “We believe, our Artificial Intelligent Robots will create many new jobs in New Zealand and Australia”.
The company’s plan is to launch this type of machine in Australia at the end of this year.
The Medsilica-Promobot Artificial Intelligent Robots are used in many fields: Airports, Security , Banks, Universities, Insurance companies, Councils, Museums, etc.
Enterosgel, batch #L309170051, has been tested by the Britain National Measurement Laboratory and Designated Institute (LGC) for a wide range of substances banned by WADA (the World Anti Doping Agency) to provide the highest level of assurance that they are safer for athletes to use.
LGC is a World Class sports doping control and research laboratory, with more than 50 years of leadership in drug surveillance in sport.
Ryan Bellone | Business Development Manager | Sport and Specialized Analytical Services | Standards | Mobile: +1 206-452-4948 | firstname.lastname@example.org | Skype: lgc.ryan.bellone |
LGC Lexington | 1745 Alysheba Way, Suite 160 | Lexington | Kentucky | 40509 | USA |
LGC Fordham | Newmarket Road | Fordham | Cambridgeshire | CB7 5WW | UK |
informed-choice.org | informed-sport.com | lgcgroup.com
Irrespective of the type of diarrhoea, probiotics, enterosorbents and medications of immunomodulatory action should be considered alternative to antibiotics and chemotherapeutic agents for starting etiotropic therapy of mild, moderate, even severe forms of Acute intestinal infections in children (under condition of starting treatment on day 1-2 of the disease).
Enterosgel is an intestinal absorbent (enterosorbent) intended to be used as an adjuvant to standard rehydration therapy and in the management and reduction of stomach and intestinal illness symptoms.
T.L. Protsyuk, N.I. Tocarchuk, L.A. Protsyuk, О. V. Chirkа, N.M. Surkovа, L.D. Kotsur
National Pirogov Memorial Medical University, Vinnytsya Regional Children’s Clinical Hospital
MATERIAL AND METHODS OF THE STUDY
90 infants in the first year of life with severe (45 patients) and moderate (45 patients) atopic dermatitis (group 1) and 50 patients in the first year of life with mild forms of atopic dermatitis – (group 2) were examined. Follow-ups of children were carried out during 4 years.
In July 2017, the manufacture in Europe dispatched Enterosgel in tubes to New Zealand. There was a shortage of Enterosgel because a great demand in Europe. The official Enterosgel warehouse in New Zealand (Australaia) sold out Enterosgel in tubes in May 2017.
Enterosgel in tubes 225gr and 90gr will be available in New Zealand and Australia in August 2017.